

IN THE CLAIMS:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A vaccine ~~against malaria~~ comprising ~~*P. falciparum*~~ a C-terminal 42 kD fragment of merozoite surface protein-1 (MSP-1₄₂) from *P. falciparum* 3D7, SEQ ID NO:2, that is recombinantly expressed in *E. coli* as a soluble protein that retains its native structure and an adjuvant selected from the group consisting of A, B, C, D, and E.
2. (Cancelled)
3. (Currently amended) A method for inducing an immune response to malaria in a subject ~~an immune response against malaria infection~~ comprising administering to said subject a composition comprising an immunologically effective amount of ~~*P. falciparum*~~ C-terminal 42 kD fragment of merozoite surface protein-1 (MSP-1₄₂) from *P. falciparum* 3D7, SEQ ID NO:2, that is recombinantly expressed in *E. coli* as a soluble protein that retains its native structure in an acceptable diluent and an adjuvant chosen from the group consisting of A, B, C, D, and E.
4. (Cancelled)
5. (Currently amended) A method for inducing a protective immune response to malaria in a mammal, comprising
administering a composition comprising a ~~*P. falciparum*~~ MSP-1₄₂ from *P. falciparum* 3D7, SEQ ID NO:2, that is recombinantly expressed in *E. coli* as a soluble protein that retains its native structure in an amount effective to induce an immune response in said mammal and an adjuvant selected from the group consisting of A, B, C, D, and E.
6. (Cancelled)
7. (Original) The method of claim 5, wherein the composition is administered to the individual in an amount of 50 ug per dose.
8. (Original) The method of claim 5, wherein the composition is administered parenterally.
9. (Original) The method of claim 5, wherein the composition is administered intranasally.
10. (Original) The method of claim 5, wherein said administration is a multiple administration.
11. (Original) The method according to claim 10 wherein said multiple administration is at 0 and

Lyon et al. -- Appl. No. 10/057,532

6 months.